Inclusion Criteria:

          1. Male, age 45 to 80 years

          2. Biopsy-confirmed adenocarcinoma of the prostate. Biopsy (minimum 10 cores) obtained ≥
             6 weeks and ≤ 6 months before treatment (or at the discretion of PI and approval by
             the Sponsor).

          3. Clinical stage ≤ T2b

        4.1 Gleason score ≤ 3 + 4 (Part I only)

        4.2 Gleason score 3+4 (Part II only) *now recruiting

        5. PSA ≤ 15 ng/ml

        6. Eligible for MRI [Form GCP-10131]

        7. Eligible for general anesthesia (ASA category ≤ 3)

        8. Prostate volume ≤ 90 cc, on Baseline MRI

        9. Prostate size ≤ 5.0 cm in sagittal length, and ≤ 6.0 cm in axial diameter, on Baseline
        MRI

        10. Life expectancy ≥ 10 years

        11. No calcifications in the planned ultrasound beam path, or at the discretion of the
        investigator with approval from the Sponsor.

        Exclusion Criteria:

          1. Evidence (including Baseline MRI and bone scan) of extracapsular extension, sphincter
             involvement, seminal vesicle invasion, lymph node invasion or metastases

          2. Suspected tumour on Baseline MRI within 3 mm of the prostatic urethra, or in the
             prostate apex within 3 mm from the sphincter plane

          3. Prior definitive treatment of prostate cancer

          4. Prior transurethral resection of the prostate (TURP)

          5. Use of 5-alpha reductase inhibitors (5-ARIs) or hormone therapy within 3 months prior
             to the baseline visit. Baseline PSA must be established after a minimum of 3 months
             following 5-ARIs discontinuation. Additionally, use of 5-ARIs is not permitted
             following treatment during the study follow-up period.

          6. Prostate calcifications > 1 cm in largest diameter, on Baseline Ultrasound

          7. Cysts > 1 cm in largest diameter, on Baseline MRI

          8. Bleeding disorder (INR > ULN and PTT > ULN)

          9. Abnormal coagulation and current anticoagulant therapy. Patients whose anticoagulation
             therapy can be temporarily reversed within 7 days prior to treatment are eligible.
             Platelet inhibitors (ie: ASA) and heparin are not exclusion criteria.

         10. Acute unresolved Urinary Tract Infection (UTI)

         11. Interest in future fertility

         12. History of any other malignancy other than skin cancer, or low grade bladder cancer
             which has been completely resected, within the previous 2 years. Patients that have
             had curative treatment of a previous malignancy and no recurrence of that malignancy
             within the past 2 years will be allowed.

         13. Patients with peripheral arterial disease with intermittent claudication or Leriches
             Syndrome

         14. Patients with diabetes who have evidence of complications from their diabetes, such as
             end organ sequelae of diabetes or Hemoglobin A1c > 7%.

         15. History of any major rectal or pelvic surgery or radiotherapy

         16. History of ulcerative colitis or other chronic inflammatory conditions affecting
             rectum (includes rectal fistula, anal stenosis)

         17. Documented clinical prostatitis requiring therapy within 6 months prior to Treatment

         18. History of urethral and bladder outlet disorders, including urethral stricture
             disease, urethral diverticulae, bladder neck contracture, urethral fistulae, urethral
             stenting, urethral sling, urethroplasty or chronic indwelling urethral catheter

         19. Patients with artificial urinary sphincter or any penile implant

         20. Severe neurogenic bladder

         21. Untreated bladder stones

         22. History of acute urinary retention within the last 12 months

         23. Active untreated gross hematuria for any cause

         24. Post Void Residual (PVR) bladder volume > 250 mL

         25. Obstructing median lobe enlarged out of proportion to the rest of the prostate and
             protruding significantly into the bladder, sometimes referred to as "ball valve"
             median lobe, determined on Baseline MRI

         26. Any prostate related investigational therapy within 6 months of Visit 1

         27. History of Parkinson's disease or multiple sclerosis

         28. History of drug abuse

         29. Known infectious disease including HIV positivity or AIDS-related illness, HBV and HCV

         30. Current unilateral or bilateral hydronephrosis

         31. Allergy or contraindications to administration of the GI anti-spasmodic drug:

               1. Patients in the USA: Glucagon

               2. Patients in Canada and Europe: Buscopan (Hyoscine)

         32. Contraindications to administration of gadolinium-based MRI contrast agent (e.g.
             Magnevist), such as chronic, severe kidney disease, acute kidney injury, history of
             Sickle Cell Disease, history of anemia, or intolerance/allergy to the contrast agent

         33. Other severe, acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results